Abstract
Background:
Snakebite is a major cause of mortality and morbidity in many areas, particularly in the rural tropics, and is a major public health problem around the world. It also imposes significant economic burdens on snakebite victims due to treatment-related expenses and lost productivity.
Objective:
The purpose of this study was to assess seasonal variation, treatment outcomes, and its associated factors among snakebite in Denan health center in the Somali region, Ethiopia.
Method:
A facility-based cross-sectional study was conducted from 10 to 30 September 2020 in Denan health center, Somali region, Ethiopia. All snakebite cases in Denan health center from 1 September 2015 to 31 August 2020 were included. Data were collected using a pre-tested structured checklist from the patient cards. Data were entered into EpiData version 3.1 and analyzed using SPSS version 22 (IBM SPSS Statistics, 2013). The prevalence was reported by proportion with 95% confidence interval (CI) and summary measures. Predictors were assessed using a multivariable logistic regression analysis model and reported using an adjusted odds ratio with 95% CI. Statistical significance was declared at p-value < 0. 05.
Result:
The overall prevalence of poor outcome of venomous snakebites was 31.4% (95% CI 26.3% 35.4%). Study participants with an age of less than 10 years old (AOR = 2.01; 95% CI 1.39, 4.05), age between 10 and 30 years old (AOR = 2.06; 95% CI 1.39, 9.30), arrival times greater than or equal to 6 hours (AOR = 2.37; 95% CI 1.39, 4.05), and timing of snakebite (AOR = 0.49; 95% CI 0.31–0.87) were factors found to be significantly associated with poor treatment outcome.
Conclusion:
According to this study, about one in every three snakebite patients have a poor outcome. Patients with poor outcomes were those who did not improve as a result of treatment or died as a result of it. Designing appropriate engagement of public health education about snakebite prevention techniques, particularly during entry and exit of rainy seasons and establishment of appropriate case management protocol is strongly recommended, as well as increasing the accessibility or availability of antivenoms will undoubtedly have a significant impact on the reduction of mortality and disability related to that of the snakebites.
Introduction
According to the World Health Organization (WHO), venomous snakes occur in all regions of the globe and are a public health problem, especially in tropical areas. Envenomation due to snakebites is considered one of the main neglected tropical diseases, affecting the poor rural populations of Africa, Asia, Latin America, and Oceania ().
Snakebite, particularly in the rural tropics, is a major cause of mortality and morbidity, and it has a significant impact on human health and the economy through treatment-related expenditure and loss of productivity (). Snakebite is the single most important cause of envenoming worldwide and results in substantial mortality in many parts of Africa, Asia, and America (). Snakebite is significantly neglected as a public health problem in the world as evidenced by the lack of available incidence data from most of the rural tropics where snakebites occur frequently.
Global snakebite (envenoming) incidence has been estimated as 500,000 and mortality between 30000 and 40000 per year (, ). Chippaiux estimated that venomous snakes cause 5.4 million bites, approximately 2.5 million envenomings, and over 125,000 deaths worldwide annually (). White estimated more than three million bites per year resulting in more than 150,000 deaths (). Details of the methods used to estimate these numbers have not been clearly described. More recently, Anuradhani et al. reported that globally at least 421,000 envenomings occurred annually, but this may be as high as 1,841,000 (). According to this estimate, the highest numbers of envenoming are estimated for South Asia (121,000), followed by South East Asia (111,000), and East Sub-Saharan Africa (43000).
Health systems in many countries where snakebites are common often lack the infrastructure and resources to collect basic research and statistical data on the problem. Assessing the true impact is further complicated by the fact that cases reported to health ministries by clinics and hospitals are often only a small proportion of the actual burden. This is because many victims never reach primary care facilities and are therefore unreported. This is contributed by socio-economic and cultural factors that influence treatment-seeking behavior with many victims opting for traditional practices rather than hospital care ().
Venomous snakebites can result in life-threatening medical emergencies. These include significant paralysis, which can cause breathing problems, bleeding disorders, which can result in lethal hemorrhage, irreversible kidney failure, and severe local tissue destruction, which can result in permanent disability and amputation. In many countries, effective treatment for snakebite envenoming is currently unavailable. When treatment is available, the cost can be prohibitively expensive. Long-term consequences of poor treatment can push vulnerable poor people deeper into debt and poverty ().
According to the Global Burden of Disease 2016 study, the total disability-adjusted life years lost due to venomous animal attacks in West Africa in 2016 is estimated to be around 330,000. An epidemiological survey conducted by the Ethiopian Public Health Institute in 2014 revealed that a total of 949 snakebites were identified over 10 months, with the highest number reported in Oromia, concluding that snakebite is a public issue in Ethiopia ().
The vicious cycle begins with a lack of appropriate research-based data on actual snakebite epidemiology, which leads to poor local and national health policy regarding snakebite disaster planning, decreased antivenom demand in the market, and finally reduced antivenom production by manufacturers. The vicious cycle continues, and snakes continue to be a neglected tropical disease recognized by WHO ().
In Ethiopia, available reports and research on snakebite problems are limited, and snakebite is widely regarded as a minor public health concern. However, some small-scale studies, mostly conducted in the northern part of the country, revealed the existence of the problem, with a higher mortality rate of about 14.8%. Furthermore, the experience of professional health workers working in the country's lowland regions reveals significant morbidity and mortality associated with snake accidents, particularly during rainy seasons (). As a result, the purpose of this study is to assess seasonal variation, treatment outcome, and its associated factors among the snakebite patients in the Somali region, Eastern Ethiopia.
Methods and materials
Study design, period, and area
A facility-based cross-sectional study was conducted from 10 to 30 September 2020 in Denan health center, Somali region, eastern Ethiopia. Denan district is geographically located 1123 kilometers (km) southeast of Addis Ababa, 490 km southeast of Jigjiga, and 70 km north of Godey town. Denan woreda has two health centers and nine health posts. The nearest hospitals are Godey hospital (70 km) and Kebridahar Hospital (100 km). The climate in the area is hot, harsh semi-desert weather with less rain full. The total population of Denan woreda are about 33,784 people according to the last Ethiopian national census of 2007. The study was included all snakebite patients registered from 1 September 2015 to 31 August 2020.
Study population
All snakebite cases in Denan health center from 1 September 2015 to 31 August 2020 were the study population. Since there were small numbers of source population in the study area, all snakebite cases during the study period were included. Patients with no available data or incomplete data registration were excluded.
Sample size determination and sampling procedure
The sample size was calculated by using a single population proportion formula as follows:
n = the minimum sample size required, p = estimated proportion of snakebite, and Zα/2 = the value of standard score at 95% confidence interval (1.96), with the following assumptions: Confidence level at 95% = 1.96; margin of error (d) = 0.05, and non-response rate = 10% are considered to get appropriate sample size with available resource, and the proportion of snakebite (50%) was used. The sample size was calculated as (Zα/2) 2* P(1-q) /d2 = (1.96)2 * 0.5* 0.5/ (0.05)2 = 384 by adding non-response rate (10%), and the final sample size was 422.
Because the total number of admissions at Denan Health Center from 1 September 2015 to 31 August 2020 were 430, all snakebite victims who visited the facility were included.
Data collection method and procedure
A structured pre-tested extraction sheet adopted from previous similar studies was used to collect data (–). The extraction sheet includes socio-demographic characteristics of the study participants, characteristics of snakebite events, clinical presentations, interventions and outcomes of snakebite, and seasonal variation of snakebite. The tool was prepared in the English version. The data extraction was performed by well-trained 10 Bachelor of Science holding Nurses and supervised by two Master of Science-holding Nurses. Before starting data collection, the medical registration number (MRN) of all snakebite patients were traced from the emergency and ward (inpatient) logbooks and by using the list of organized chart numbers, and medical charts were collected from the card room. Then, all necessary information were retrieved from medical charts.
The quality of the data was guaranteed by pretesting using 5% of the respondents who were not eligible for the study before actual data collection. The completeness of the data was checked daily.
Operational definition
The treatment outcome of snakebite cases that were treated in the health center was categorized as poor (when a patient died or had permanent physical damage or debilitation, such as amputation of a limb or organ failure) or good (an improved health condition).
Antivenom (also called antivenin): the only specific antidote to the toxins in the venom of a particular snake.
Venomous snake: snakes that inject their venoms into humans.
Non-venomous snake: snakes that do not inject venoms.
Data processing and analysis
The data were entered into Epi data statistical software version 3.1 and then exported to SPSS window version 22 for analysis. Descriptive statistical analysis was used to describe the characteristics of study participants. Then, the information was presented using frequencies, tables, and figures. Binary logistic regression was fitted to see the association between each independent variables and outcome variable. The assumptions of binary logistic regression were checked. The goodness of fit was checked by Hosmer-Lemeshow statistic and omnibus tests. All variables with P-value < 0.2 in the bivariate analysis were included in the multivariable analysis to control all possible confounders. The multi-co-linearity test was carried out to see the correlation between independent variables by using the standard error and collinearity statistics (variance inflation factors >10 and standard error >2 were considered as suggestive of the existence of multi-co-linearity). The direction and strength statistical association was measured by odds ratio with 95% CI. Adjusted odds ratio along with 95% CI was estimated to identify the association between independent variables and treatment outcome of snakebite by using multivariable analysis. In this study, P-value < 0.05 was considered to declare a statistically significant result.
Result
Socio-demographic characteristics
During the 5 years, there were 430 snakebite cases. “Nearly three-fourths [310 (72.1%)] of the study participants were below 25 years.” The majority of the study participants were males [255 (59.3%)], single in marital status [295 (68.6%)], and rural residents [315 (73%)] (Table 1).
Table 1
| Variable | Category | Frequency (n = 430) | Percent (%) |
|---|---|---|---|
| Age | Below 9 years | 170 | 39.5 |
| 10–25 years | 140 | 32.6 | |
| 26–40 years | 75 | 17.4 | |
| 41–55 years | 20 | 4.7 | |
| >56 years | 25 | 5.8 | |
| Gender | Male | 255 | 59.3 |
| Female | 175 | 40.7 | |
| Marital | Single | 295 | 68.6 |
| Married | 135 | 31.4 | |
| Address | Rural | 315 | 73.3 |
| Urban | 115 | 26.7 | |
| Educational Status | Illiterate | 95 | 22.1 |
| Can read and write | 190 | 44.2 | |
| Primary school | 100 | 23.3 | |
| Secondary school | 35 | 8.1 | |
| College and above | 10 | 2.3 | |
| Occupation | Farmer | 30 | 7.0 |
| Animal herding | 60 | 14.0 | |
| Housewife | 65 | 15.1 | |
| Daily labor | 20 | 4.7 | |
| Government employee | 10 | 2.3 | |
| Merchant | 25 | 5.8 | |
| Others* | 220 | 51.2 |
Socio-demographic characteristics of study participants at Denan health center, Shabelle zone, Somali region, Ethiopia.
Private workers, students.
Characteristics of snakebite events
Among the study participants, 155 (36%) snakebite cases have occurred during daytime outdoors. Nearly, one-fourth [120 (27.9%)] of the cases the snake attack occurred during sleeping time. The lower extremity was the most common anatomic site for snakebite [190 (44.2%)] followed by the upper extremity [130 (30.2%)]. The majority [350 (81.4%)] of snakebites were venomous bites. Three hundred forty (44.2%) of the study participants arrived at the health institution as an emergency case after 6 hours of the accident. More than half [235 (54.7%)] of the patients were discharged within the first 24 hours of admission (Table 2).
Table 2
| Variable | Category | Frequency(n = 430) | Percent (%) |
|---|---|---|---|
| Timing of bite | Day time indoors | 85 | 19.8 |
| Day time outdoors | 155 | 36.0 | |
| Night time indoors | 140 | 32.6 | |
| Night time outdoors | 50 | 11.6 | |
| Place during bite | Snake in the house | 155 | 36.0 |
| Snake in a ground hole | 95 | 22.1 | |
| Snake in the bush and grassland | 150 | 34.9 | |
| Snake in the garbage around the house | 30 | 7.0 | |
| Activities during bite | Walking in the bush | 220 | 51.2 |
| Cleaning garbage | 40 | 9.3 | |
| Sleeping in the home | 120 | 27.9 | |
| Trying to kill the snake | 50 | 11.6 | |
| Affected body parts | Head and neck region | 45 | 10.5 |
| Upper extremities | 130 | 30.2 | |
| Chest | 10 | 2.3 | |
| Abdomen | 15 | 3.5 | |
| Back and pelvic | 25 | 5.8 | |
| Lower extremities | 190 | 44.2 | |
| Spitting eyes | 15 | 3.5 | |
| Characteristics of bite | Dry bite | 65 | 15.1 |
| Non-dry bite | 350 | 81.4 | |
| Spitting in the eyes of the victim | 15 | 3.5 | |
| Arrival time at the health facility | Within 1 h | 30 | 7.0 |
| 2–3 h | 20 | 4.7 | |
| 3–4 h | 10 | 2.3 | |
| 4–6 h | 30 | 7.0 | |
| >6 h | 340 | 44.2 | |
| Health facility stays | Less than one day | 235 | 54.7 |
| 1–5 days | 100 | 23.3 | |
| 6–10 days | 55 | 12.8 | |
| 11–15 days | 10 | 2.3 | |
| >15 days | 30 | 7.0 |
Characteristics of snakebite among study participants at Denan health center, Shabelle zone, Somali region, Ethiopia.
Clinical presentations, interventions, and outcomes of snakebite
The most common clinical manifestations in snakebite patients were localized symptoms such as pain (24.4%), swelling (31.4%), and soft tissue necrosis (29.1%) around the area of snakebite. Among study participants, 380 (88.4%) did not have clinical features of systemic envenomation with variable severity range. More than one-third [160 (37.3%)] of study participants had any traditional remedies before presenting to the health center (Table 3).
Table 3
| Variables | Categories | Frequency | Percentage |
|---|---|---|---|
| Clinical presentations | Only fang marks | 65 | 15.1 |
| Local pain | 105 | 24.4 | |
| Local swelling | 135 | 31.4 | |
| Local tissue necrosis | 125 | 29.1 | |
| Neurologic disorders | 15 | 3.5 | |
| Bleeding disorder | 15 | 3.5 | |
| Anaphylactic shock and hemodynamic instability | 20 | 4.7 | |
| No systemic envenomation | 380 | 88.4 | |
| Traditional medication used | Herbal medication | 100 | 23.3 |
| Tourniquet applied | 60 | 14.0 | |
| None | 270 | 62.8 | |
| Treatment provided | Analgesia-only | 220 | 51.2 |
| Analgesia + IV fluid (colloid) | 75 | 17.4 | |
| Daily wound care + wound debridement + TAT, antibiotics | 135 | 31.4 | |
| Treatment outcome | Improved and discharged | 295 | 68.6 |
| Referred to higher hospital | 20 | 4.7 | |
| Local tissue loss | 90 | 20.9 | |
| Limb amputation | 5 | 1.2 | |
| Death | 20 | 4.7 | |
| Referral | For mechanical ventilation | 5 | 1.2 |
| For amputation | 10 | 2.3 | |
| For blood transfusion | 10 | 2.3 | |
| For fasciotomy | 5 | 1.2 | |
| None | 390 | 90.7 | |
| Renal failure | 10 | 2.3 |
Clinical presentations, interventions, and outcomes of snakebite among study participants at Denan health center, Shabelle zone, Somali region, Ethiopia.
IV = Intravenous; TAT = Tetanus antitoxin.
Most of patients were given supportive care including pain and fluid management, with local wound care and antibiotics. There was no registration of any patient received antivenom in the health center. The overall prevalence of poor outcome of venomous snakebites was 31.4% [95% CI 26.3% 35.4%]. Among study participants, 4.7% of study participants died in a health center due to a snakebite. Regarding major clinical manifestations, bleeding (2.3%), and amputation (2.3%) were the most common (Table 3).
Seasonal variation of snakebite
The entry and exit of rainy seasons of the year were associated with an increase in the frequency of snakebite, with April to June and October to December having the highest snakebite occurrence (Figure 1). The frequency of snakebite decreased from 2016 to 2020 (Figure 2).
Figure 1
Figure 2
Factors associated with snakebite outcome
In the final multivariable logistic regression model, variables such as the age of patient, residency, arrival time, and timing of snakebite were significantly associated with poor outcomes. The odds of having poor outcomes among study participants aged below 10 years and 10–30 years were 4.63 times ([AOR = 4.63, 95% CI (2.13–11.38)] and 2.42 times [AOR = 2.42, 95% CI (1.39–9.30)]) higher than those participants aged above 30 years. Urban residents had 44% reduction [AOR = 0.56, 95% CI (0.06–0.97)] of poor outcomes than those study participants residing in rural. Those participants who had suffered the snakebite at daytime were 51% reduced [AOR = 0.49, 95% CI (0.31–0.87)] to have poor outcome compared to those who suffered snakebite at night time. Those patients who arrived late at the health facility for more than 6 hours were 2.01 times [AOR = 2.01, 95% CI (1.39–4.05)] more likely to have poor outcomes than their counterparts (Table 4).
Table 4
| Variable | Outcome | COR 95% CI | AOR 95% CI | P-value | |
|---|---|---|---|---|---|
| Poor | Good | ||||
| Residence | |||||
| Urban | 35 (30.4%) | 80 (69.6%) | 0.94 (0.14–0.99) | 0.56 (0.06–0.97) | 0.01 |
| Rural | 100 (31.7%) | 215 (68.3%) | 1 | 1 | |
| Sex | |||||
| Male | 90 (35.3%) | 165 (64.7%) | 1.58 (1.01–2.90) | 1.56 (1.21–3.44) | 0.228 |
| Female | 45 (25.7%) | 130 (74.3%) | 1 | 1 | |
| Age | |||||
| Less than 10 years | 80 (47.1%) | 90 (52.9%) | 9.7 (4.78–19.96) | 4.63 (2.13–11.38) | 0.001* |
| 10–30 yrs | 45 (32.1%) | 95 (67.9%) | 5.21 (1.36–8.72) | 2.42 (1.39–9.30) | 0.001* |
| Above 30 yrs | 10 (8.3%) | 110 (91.7%) | 1 | 1 | |
| Educational status | |||||
| Cannot read and write | 55 (57.9%) | 40 (42.1%) | 1.15 (1.01–6.81) | 2.01 (0.75–5.44) | 0.168 |
| Primary school | 60 (31.6%) | 130 (68.4%) | 1.67 (1.37–3.64) | 1.50 (0.26–3.13) | 0.873 |
| Secondary school | 15 (30.0%) | 35 (70.0%) | 0.35 (0.02–3.42) | 1.84 (0.87–9.30) | 0.084 |
| College and above | 6 (54.5%) | 5 (45.5%) | 1 | 1 | |
| Timing of snakebite | |||||
| Day time | 65 (27.1%) | 175 (72.9%) | 0.637 (0.04–0.96) | 0.49 (0.31–0.87) | 0.02* |
| Nighttime | 70 (36.8%) | 120 (63.2%) | 1 | 1 | |
| Arrival time | |||||
| 6 hours and above | 40 (44.4%) | 50 (55.6%) | 2.06 (1.24–3.33) | 2.01 (1.39–4.05) | 0.001* |
| Less than 6 hours | 95 (27.9%) | 245 (72.1%) | 1 | 1 | |
Factors associated with outcome among snakebite patients attending Denan health center, Ethiopia, 2020.
Discussion
This study assessed the clinical presentations, interventions, treatment outcomes of snakebites, and their associated factors in the Denan health center in the Somali region, Eastern Ethiopia. It revealed that 4.7% of them have died in the health center due to snakebite from 1 September 2015 to 31 August, 2020. Moreover, this study pointed out that bleeding (3.5%), amputation (2.3%), and renal failure (2.3%) were the most common clinical manifestations. Age of patient, residency, arrival time, and timing of snakebite were identified as predictors of poor treatment outcome.
In this study, the poor treatment outcome among the snakebite patients was 31.4% [95% CI 26.3% 35.4%]. It also showed that 20 (4.7%) of the 430 patients who were bitten by a snake died. This is consistent with the study conducted in Nepal () and Zimbabwe (). Taking into consideration the population that resides in the catchment area and uses Denan health center for health services, one possibly says that death from the snakebites was high. This is much higher than the study conducted in the most developed country while much lower than the study conducted in developing country (). This high death rate could be attributed to a lack of antivenom and late arrival at the health center, both of which play a critical role in the death of snakebite patients (, ).
In this study, monthly admissions to the health center showed a clear seasonal trend between 2015 and 2020, with the majority of patients admitted between April and June and October and December. In Ethiopia, it is crystal clear that these months, such as April and June, are a rainy season during which labor-intensive agricultural activities such as land preparation for planting and sowing, as well as weeding, are carried out. To that end, an increased number of workers will be exposed to the field, potentially making them vulnerable to snakebites. This is in harmony with the study conducted in California (), Costa Rica (), and Brazil (). This is due to the fact that the start of the rainy season coincides with an increase in the number of accidents, a situation that has been reported in other tropical regions (–). Furthermore, the rainy season coincides with the birth season of several snake species, which contributes to an increase in the number of snakebites (). Similarly, this study found an increase in snakebite accidents during the months of October and November. This finding is supported by studies conducted in Brazil () and California (). One possible explanation is that this is a month when there is a lot of harvesting going on, which exposes workers to snakebites.
According to this study, the odds of having poor outcomes among study participants aged below 10 years and 10–30 years were 4.63 and 2.42 times higher than those participants aged above 30 years ([AOR = 4.63, 95% CI (2.13–11.38)] and [AOR = 2.42, 95% CI (1.39–9.30)]), respectively. This is in line with a study conducted in Costa Rica (). One possible explanation would be that young people are more exposed to snakebite due to their greater activity in the field. Another possible reason could be because of the relative frequency of each age group in the population. Furthermore, if snakebites occur in children, the likelihood of a poor treatment outcome increases. This could be related to the fact that as people get older, their level of caution increases, which plays a critical role in their ability to avoid being harmed by snakes. Furthermore, bites in children are more complicated than bites in adults, presumably owing to their lower body mass and faster absorption (28).
In this study, those who were urban residents had a 44% reduction of poor outcomes than those study participants residing in rural [AOR = 0.56, 95% CI (0.06–0.97)]. This is in line with the study conducted in Northwest Ethiopia (29). One possible reason is that they are more likely to arrive at the health center quickly because they are in a nearby health center, as opposed to those who come from a remote area and thus receive timely care and management. Furthermore, those who live in urban are more likely to accept treatment-related advice than those who live in rural areas, which may have a positive effect on treatment outcomes.
According to the findings of this study, those who were bitten by a snake during the day had a 51% lower chance of having a poor outcome than those who were bitten at night [AOR = 0.49, 95% CI (0.31–0.87)]. The possibility is that the likelihood of receiving treatment will increase because means of transportation are more easily available during the day, increasing the likelihood of arriving at a health center where treatment is provided. Furthermore, the depth and intensity of bites at night may be severe, as darkness may prevent victims from being protected from snakebites.
The finding from this study revealed that those patients who arrived late at the health facility after more than 6 hours were 2.01 times more likely to have poor outcomes than their counterparts [AOR 2.01, 95% CI (1.39–4.05)]. This is in line with the study conducted in Brazil (). This is because the time between treatment and initiation of medical care is directly correlated. Thus, time to treatment variables is related to the severity of snakebite envenomation.
Conclusion
According to the study, about one in every three snakebite patients have a poor outcome. Designing appropriate engagement of public health education about snakebite prevention techniques, particularly during the entry and exit of rainy seasons and establishment of appropriate case management protocol is strongly recommended, as well as increasing the accessibility or availability of antivenoms, will undoubtedly have a significant impact on the reduction of mortality and disability related to that of the snakebites.
Funding
Haramaya University provided financial support for this study. However, the funding agency had no role in the collection, analysis, and interpretation of the data as well as the writing of the manuscript.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by Haramaya University College of Health and Medical Sciences, Institutional Health Research Ethics Review Committee (IHRERC). The participants provided their written informed consent to participate in this study.
Author contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas, took part in drafting, revising, or critically reviewing the article, gave final approval of the version to be published, have agreed on the journal to which the article has been submitted, and agree to be accountable for all aspects of the work.
Acknowledgments
The authors are very thankful to Haramaya University, the study participants, data collectors, and field supervisors.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
AbebeMABirhanuHBethlehemNGezahegnKSisayKAmhaKet al. Epidemiological survey of snake bite in Ethiopia. Epidemiol Open Access. (2014) 4:1165–2161.
2.
BathulaNKChowdhuryB. International journal of basic and clinical pharmacology. Int J Basic Clin Pharmacol. (2019) 8:1758. 10.18203/2319-2003.ijbcp20193174
3.
Bravo-VegaCACordovezJMRenjifo-IbáñezCSantos-VegaMSasaM. Estimating snakebite incidence from mathematical models: a test in Costa Rica. PLoS Neglect Tropical Dis. (2019) 13:e0007914. 10.1371/journal.pntd.0007914
4.
ChippauxJPWilliamsVWhiteJ. Snake venom variability: methods of study, results and interpretation. Toxicon. (1991) 29:1279–303. 10.1016/0041-0101(91)90116-9
5.
CurrieBJSmithAMSutherlandSKHudsonB. An epidemiological study of snake bite envenomation in Papua New Guinea. Med J Aust. (1991) 154:266–8. 10.5694/j.1326-5377.1991.tb121088.x
6.
FaizmaHMYounusADasebLKarimJC. A hospital based survey ofsnake bite in Chittagong Medical College. J Bangladesh College Phys Surgeons. (1995) 13:3–8.
7.
González-AndradeFChippauxJ. Snake bite envenomation in Ecuador. Trans Royal Soc Tropical Med Hygien. (2010) 104:588–91. 10.1016/j.trstmh.2010.05.006
8.
GutiérrezJMTheakstonDWarrellDA. Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Med. (2006) 3:150. 10.1371/journal.pmed.0030150
9.
HardyDL. Bothrops asper (Viperidae) snakebite and field researchers in middle America. Biotropica. (1994) 26:198–207. 10.2307/2388809
10.
HayesWKHerbertSSRehlingGCGennaroJF. Factors that influence venom expenditure in viperids and other snake species during predatory and defensive contexts. Biol Vipers. (2002) 207–33.
11.
IsbisterGKGraudinsAWhiteJWarrellD. Antivenom treatment in arachnidism: antivenoms. J Toxicol Clin Toxicol. (2003) 41:291–300. 10.1081/CLT-120021114
12.
WhiteJ. Bites and stings from venomous animals: a global overview. Therapeutic Drug Monitor. (2000) 22:65–68. 10.1097/00007691-200002000-00014
13.
ChippauxJP. Snake-bites: appraisal of the global situation. Bull World Health Organ. (1998) 76:515–24.
14.
KasturiratneAWde SilvaNGunawardenaNKPathmeswaranA. The global burden of snake bite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. (2008) 5:218. 10.1371/journal.pmed.0050218
15.
MartinsSBBolonIAlcobaGOchoaCTorgersonPSharmaSKet al. Assessment of the effect of snakebite on health and socioeconomic factors using a One Health perspective in the Terai region of Nepal: a cross-sectional study. Lancet Global Health. (2022) 10:e409–e415. 10.1016/S2214-109X(21)00549-0
16.
MeyerWPHabibAGOnayadeAAYakubuASmithDCNasidiAet al. First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom. Am J Trop Med Hyg. (1997) 56:291–300. 10.4269/ajtmh.1997.56.291
17.
MiseYFLira-da-SilvaRMCarvalhoFM. Time to treatment and severity of snake envenoming in Brazil/ Tiempo hasta el tratamiento y gravedad del envenenamiento por mordedura de serpiente en el Brasil/Tempo para tratamento e gravidade do envenenamento ofidico no Brasil. Revista Panamericana de Salud Publica. (2018) 42:1–6. 10.26633/RPSP.2018.52
18.
MugutiGIMarambaAWashayaCT. Snake bites in Zimbabwe: a clinical study with emphasis on the need for antivenom. Cent Afr J Med. (1994) 40:83–8.
19.
MustaphaSJ. Snake bite in Gombe. Highland Med Res J. (2003) 1:22–7. 10.4314/hmrj.v1i4.33819
20.
PhillipsCLipmanGSGugelmannHDoeringKLungD. Snakebites and climate change in California, 1997–2017. Clin Toxicol. (2019) 57:168–74. 10.1080/15563650.2018.1508690
21.
SasaMSegura CanoSE. New insights into snakebite epidemiology in Costa Rica: a retrospective evaluation of medical records. Toxicon X. (2020) 7:100055. 10.1016/j.toxcx.2020.100055
22.
SanjibK. Snake Bites and Dog Bites in Nepal: Community Based Studies on Snake Bites and Dog Bites.Department of Medicine, B P Koirala Institute of Health Sciences, presentation made at the WHO first Consultative Meeting on Rabies and Envenomings: Geneva (2007).
23.
SteegemansISisayKNshimiyimanaEGebrewoldGPieningTMenberu TessemaEet al. Treatment outcomes among snakebite patients in north-west Ethiopia—A retrospective analysis. PLOS Neglected Tropical Dis. (2022) 16:e0010148. 10.1371/journal.pntd.0010148
24.
SwaroopS. Snakebite mortality in the world. Bull World Health Organiz. (1954) 10:35–76.
25.
TameruK. Snake bite envenomation at Aysha refugee camp health center. Ethiopian Med J. (2006) 44:75–9.
26.
WhiteJEddlestonMCurrieBJWhyteM. Clinical toxicology. Clin Toxicol. (2003) 41:263–76. 10.1081/CLT-120021112
27.
WilliamsDGutiérrezJMHarrisonRWarrellDAWhiteJWinkelKDet al. The global snake bite initiative: an antidote for snake bite. Lancet. (2010) 375:89–91. 10.1016/S0140-6736(09)61159-4
Summary
Keywords
seasonal variation, treatment outcome, snakebites, associated factors, Ethiopia
Citation
Abdullahi A, Yusuf N, Debella A, Eyeberu A, Deressa A, Bekele H, Ketema I, Abdulahi IM and Weldegebreal F (2022) Seasonal variation, treatment outcome, and its associated factors among the snakebite patients in Somali region, Ethiopia. Front. Public Health 10:901414. doi: 10.3389/fpubh.2022.901414
Received
21 March 2022
Accepted
09 August 2022
Published
27 September 2022
Volume
10 - 2022
Edited by
Jose Luis Perez-Diaz, Universidad de Alcala, Spain
Reviewed by
Pertti Juhani Hakkinen, National Library of Medicine (NIH), United States; Gamal Eldin Abbas Khalifa, Egyptian Resuscitation Council (EgRC), Egypt
Updates
Copyright
© 2022 Abdullahi, Yusuf, Debella, Eyeberu, Deressa, Bekele, Ketema, Abdulahi and Weldegebreal.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Adera Debella aksanadera62@gmail.com
This article was submitted to Disaster and Emergency Medicine, a section of the journal Frontiers in Public Health
†ORCID: Adera Debella orcid.org/0000-0002-8060-0027
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.